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India and China are important players in an evolving process of
globalization of research and development (R&D). Focusing  on
pharmaceuticals and biotechnology industries, this paper analyses the
challenges and prospects facing the two countries in global innovation.
Large supplies of highly skilled professionals and well-established science
and technology infrastructures are important assets for India and China
in the era of globalization of R&D. At the same time, however, there is a
concern that as globalization of R&D gathers steam, the poor in India,
China and other developing countries are likely to be left out of the new
innovations. A good example is the case of India’s pharmaceuticals
industry. The leading Indian pharmaceutical firms have responded well
to the challenge of a strict intellectual property rights (IPR) regime by
increasing their R&D spending and, simultaneously, targeting their sales
to the generic drugs markets in North America and Europe. But even as
India’s top drug firms have been growing in technological capabilities
and taking part in the globalization of pharmaceuticals R&D, they have
also been shifting their focus away from the market for medicines for
poor patients.
Keywords:  India,  China,  innovation,  pharmaceuticals,
biotechnology1
1. Introduction
India and China are important players in an evolving process of
globalization of research  and development  (R&D). Focusing  on
pharmaceuticals and biotechnology industries, this paper analyses the
challenges and prospects facing the two countries in global innovation.
World Investment Report 2005 points out that there is now a
fresh wave of R&D investments by multinational corporations (MNCs) in
developing countries, particularly China and India. In a survey of the world’s
largest R&D spending MNCs conducted by the United Nations Conference
on Trade and Development (UNCTAD) in 2004-05, China was identified by
the respondents as the most attractive location for future investments in
R&D. India was the third most attractive location, behind the United States
(US) (UNCTAD, pp.22-6). The Economist described India and China as
‘high-tech hopefuls’ in a special report on technology in the two countries
in its November 2007 issue.1 Foreign direct investment (FDI), especially
in technology-intensive industries, used to be circulated largely within
developed countries. MNCs restricted their R&D activities in developing
countries mostly to the adaptation of technologies for local markets
(Kleinknecht and Wengel, 1998). Therefore, the recent interest shown by
MNCs in shifting some of their core innovation activities to China and
India marks the blossoming of a process of globalization of R&D.
There are many factors behind the growing prominence of India
and China as R&D locations. The large supply of skilled professionals in
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these countries at relatively low costs is a highly crucial one. India and
China have made significant public investments in science and technology
over the past decades, and this provides a strong base for future growth.
Also, both countries have, in recent years, introduced rules ensuring
greater protection to intellectual property rights (IPRs), in compliance
with World Trade Organization (WTO)’s Agreement on Trade Related
Aspects of Intellectual Property Rights (TRIPS). Assurance of IPR protection
has been an important incentive for MNC investments. Furthermore, the
expanding numbers of middle class consumers in India and China
promises a booming market for high-tech products, and this raises interest
levels among multinational corporations.
At the same time, the challenges unfolding are many as
outsourcing of innovation by global corporations picks up speed. First,
there are concerns on the future supply for the vast market for innovative
products for the poor in developing countries. There exists demand for
cheap medicines for poor patients, demand for biotechnological
innovations that ensure food security in the third world, demand for novel
telecommunication devices for rural areas, and  so on.  Leading
corporations in the West have so far given a low priority to this market,
focusing instead on the market for innovations for rich consumers. It
appears that the rise of India and China as favoured destinations for
outsourcing of R&D is not likely to give any positive impetus to innovations
targeting the poor. The IPR rules implemented by India and China
encourage MNC investments, but also create new constraints for domestic
firms in these countries. Many of the top domestic firms in China and
India will benefit from the growing opportunities for contract research,
but in the process they might concentrate their efforts to the innovation
needs of the rich.
Secondly, as domestic firms in India and China progressively
move away from their home markets and carry out R&D for export
markets, questions are raised on their long-term growth prospects
vis-à-vis Western MNCs. Will they grow capable of challenging Western
MNCs, or remain as junior partners in a global chain of innovation?
Evidence from India’s software industry indicates that its extreme reliance
on export markets is likely to be a constraint on future growth. D’Costa
(2002, 2004) argues that India’s software industry is overly dependent
on a single export market (the US market), locking the industry into a
low innovation trajectory.  According to Chandrasekhar (2006),
outsourcing and offshoring of business services to India aid the strategies
of US corporations to maintain their high profit levels by tapping into the
global supply of cheap labour.
This chapter discusses current and future trends in innovation in
China and India in the context of globalization of R&D, with a focus on
pharmaceuticals and biotechnology industries. The next section discusses
in greater detail the rise of India and China in the knowledge economy.
Section 3 outlines some of the features of the demand for pharmaceutical
and biotechnology innovations for the third world. Section 4 shows how
India’s pharmaceuticals industry could meet the demand for affordable
medicines, and discusses the challenges facing the industry in the
post-TRIPS phase. Section 5 is on pharmaceuticals and biotechnology
industries in China, and Section 6 concludes the paper.4 5
2. The Rise of India and China in the Knowledge
Economy
The most important factor that triggers the new wave of
investments in R&D in India and China is the large supply of highly skilled
professionals in these countries. Both China and India are now ahead of
the United States with respect to tertiary technical enrolment. In
2000-01, the total numbers of students enrolled for tertiary education
were approximately 12 million in China and 10 million in India (UNCTAD,
2005, p.162). In China, in 2004, 13.3 million students were enrolled as
undergraduates, while those enrolled for a Master’s degree and Doctor’s
degree were, respectively, 654,286 and 165,610 (National Bureau of
Statistics of China, 2005, pp. 689-95). At the same time, the costs of
employing skilled workers are relatively low in India and China. The annual
cost of hiring a chip design engineer, in 2002, was found to be $28,000 in
China (Shanghai province) and $30,000 in India compared to $300,000
in Silicon Valley in the United States (Ernst, 2005, p.56).
Both India and China have a large population of emigrants
working as skilled professionals in foreign countries. Indian professionals
accounted for 47 percent of all H-1 visas issued (to skilled workers) in
the United States in 1999; professionals from China formed the second
largest group, with a share of 5.0 per cent (cited in Chanda and
Sreenivasan, 2006, p. 220). With regard to work permits issued to
emigrants from different nationalities in the United Kingdom (UK), Indians
topped the list with a share of 21.4 percent of the total work permits
issued in 2002 (Findlay, 2006, p.78). The number of postgraduates
studying abroad has steadily increased in the case of China: from 860 in
1978 to 20,381 in 1995, and 114,682 in 2004 (National Bureau of Statistics
of China, 2005, pp. 689-95). Today, India and China are encouraging
return migration of their skilled professionals to energize high technology
entrepreneurship back home. The Chinese Academy of Sciences has
introduced many attractive schemes to woo returnee researchers as part
of a programme of ‘reverse brain drain’ currently promoted in that country
(Zweig, 2006).
The state in post-independence India actively intervened to build
a strong infrastructure for science and technology. R&D in India has been
financed largely by the public sector. The combined share of the Central
and State governments (including public sector units under their
management) in the total national expenditure on R&D in India in
2002-03 (the latest year for which data was available) was 75.6 per
cent. The share of the private sector was only 20.3 percent while higher
education accounted for the remaining 4.1 percent (GOI, 2006, pp.3-8).
In China, science and technology was a major plank in the ‘four
modernizations’ the government embarked on after 1978 (Spence, 1999,
pp.618-20). Today, the Chinese government promotes R&D through two
major national initiatives: the national high-tech R&D Programme or the
863 programme and the national programme on key basic research or
the 973 programme.2 The 973 programme has identified life sciences,
nano-technology, information technology, and earth sciences as frontier
areas for basic research. In 2004, of the total funding for science and
technology enterprises in China, 22.8 percent came directly from the
2 See the Ministry of Science and Technology of the People’s Republic of China, at
<www.most.gov.cn/eng/programmes/programmes1.htm> accessed 18 January 2006.6 7
government, 64 percent of the funds were raised by enterprises
themselves, and 6.1 percent came through loans from financial institutions
(National Bureau of Statistics of China, 2005, pp. 714-7).
2.1 Challenges Facing India and China in High Technology Sectors
While India and China enjoy some advantages in science and
technology as noted above, both countries still have a long way to go.
Table 1 shows that China and India lag clearly behind the United States
in many national-level indicators such as R&D expenditure and researchers
and patents granted per resident population. The evolving relationship
between multinational companies, on the one hand, and the state and
domestic firms in India and China, on the other, will also be highly crucial.
Dicken (1998) points out that the relationship between MNCs and states
is conflictual as well as cooperative — with each trying to gain bargaining
power over the other. In fact, according to Stopford and Strange (1991)
(cited in Dicken, 1998), the ‘balance of power’ has moved over time from
governments as a group to the multinationals.  MNCs in the United States
and Western Europe continue to reign supreme in high technology
industries, their R&D  expenditures exceeding  the national R&D
expenditures in many developing countries. For instance, R&D spending
by Pfzier of the United States in 2002 was US$4.8 billion, while the national
R&D expenditure of India in 2001 was $3.7 billion (UNCTAD, 2005,
p. 120). Given their dominant position, MNCs’ investments in India, China
and other developing countries will not be necessarily beneficial to the
host country. Local R&D firms may be taken over by MNCs; local firms
and universities may not receive fair compensation as they enter into
partnerships with MNCs; and talented researchers in local firms may
move into better paying jobs in MNCs (UNCTAD, 2005, pp.190-3).
Table 1: Selected indicators of performance in research and
development (R&D): India, China and the United States
India China    United States
R&D  expenditure,
billions of US dollars, 2002 3.7* 15.6 276.2
R&D expenditure as % of gross
domestic  product,  2000-2005 0.8 1.4 2.7
Researchers in R&D, per million
people,  1990-2005 119 708 4605
High  technology exports as
% of  manufactured  exports,  2005 4.9 30.6 31.8
Patents  granted  to  residents,
per  million  people, 2000-05 1 16 244
Notes:  *2001  data.
Sources:  UNDP (2007),  Tables  13 and 16;  UNCTAD (2005),  p.105
Studies have pointed to several areas of weaknesses in the nature
of growth of developing country firms, including China’s high-technology
firms. Lardy (2002) and Steinfeld (2004) argue that China’s integration
with the global economy has been a shallow one. In an ongoing process
of modularization in global manufacturing – in which component
manufacturing processes are spread out across locations and firms all
over the globe — Chinese firms derive weak advantages on the basis of
low costs and high volumes. China exports high-technology products but
the country’s role in these exports is limited largely to that of an assembler
of high value added components (Steinfeld, 2004). According to
Branstetter and Lardy (2006), domestic value added accounts for only 15
per cent of the value of China’s exports of electronic and information
technology products. For instance, in the case of an Apple iPod,8 9
manufactured in China by a Taiwanese company and sold for $224 (in
2005), the value captured by China was just a few dollars, whereas
Apple, an American company, claimed the largest share of profits (Linden
et al., 2007). Based on an analysis of firms in the aerospace, oil and
pharmaceuticals industries, Nolan and Zhang (2002) found that Chinese
firms were weak vis-à-vis a few leading, mostly oligopolistic, global giants,
which have emerged as core “systems integrators” in their respective
sectors. The relative weakness of Chinese firms was more marked in
high-technology sectors (Nolan and Zhang, 2002). Despite such challenges,
however, Naughton (2007) has expressed some amount of optimism on
the future of technological development in Chinese firms.
One of the important challenges to the growth of high-technology
firms in India is the limited degree of interconnection between institutional
and industrial R&D in the country. With respect to total national R&D
expenditure, government owned R&D institutions account for the major
chunk while the industrial sector’s share is small (GOI, 2006). It is debatable
whether public investments in science and technology have created strong
‘national innovation systems’ (NIS) in India.3 D’Costa (2006) argues that
the triple helix model, which refers to thick institutional linkages between
industry, academia and government, has not taken deep roots in India.
Bangalore’s software industry, for example, is characterised by high degree
of inter-firm competition — not cooperation – and limited degree of
interaction with academic and research institutions in the city (D’Costa,
2006). According to Dahlman and Utz (2005), there exists a deep gulf
between the academic world and industry in India.  However, there are
indications of positive changes occurring. A recent study by Basant and
Chandra (2007) pointed to the gradual emergence of linkages between
academia and industry in the Indian cities of Bangalore and Pune. The
study also noted that these linkages are deepening: from interactions in
the labour market to knowledge-based linkages (Basant and Chandra,
2007).
Lastly, some of the provisions of the TRIPS agreement are
creating hurdles to and, as we shall see in this chapter, altering the
nature of innovation in developing countries, especially India and China.
Drahos with Braithwaite (2002) has shown that an alliance between a
small group of United States (US) corporations and the US state was the
driver of the sequence of events linking trade and intellectual property
and culminating in the genesis of TRIPS. Representatives of US
corporations, importantly of the pharmaceutical giant Pfizer, which stood
to gain enormously from new rules on intellectual property, played an
important role in setting the government agenda on intellectual property
rights in the US. The US state took forward this agenda and, employing
a range of measures including the threat of trade sanctions through
Section 301, succeeded in bringing other developed and developing
countries into compliance on TRIPS (Drahos with Braithwaite, 2002).
The United States’ advocacy of strict patent rules in developing countries
in recent times must be seen against the fact that the IPR regimes in
advanced countries including the US during their periods of industrialization
until the early 20th century were characterized by laxity and frequent
violations (Chang, 2003). The rest of the chapter focuses on the changes 3 For a discussion on ‘national system of innovation’, see Freeman (1995).10 11
in the nature of innovation in the pharmaceuticals and biotechnology
industries in India and China, brought about to a large extent by the
TRIPS agreement.
3. Demand from Developing Countries for Innovations in
Pharmaceuticals and Biotechnology
Extreme disparities exist between the developed and developing
countries with respect to achievements in health and other human
development indicators. Majority of the world’s population living in
developing countries suffer from food shortage and lack of access to
medical facilities. A person born in Sub-Saharan Africa in 2000-05 could
be expected to live for only 49 years, whereas a person born in a high
income OECD country in the same year has a life expectancy of 79 years
(see Table 2). As Table 2 shows, significantly large proportion of the
population in Sub-Saharan Africa and South Asia are undernourished.
Tuberculosis is still highly prevalent in least-developed and developing
countries (see Table 2). Malaria cases of more than 15 per 100 population
were reported in the year 2000 in several African countries including
Botswana, Burundi, Zambia and Malawi, whereas none of the countries
in Western Europe or North America reported incidence of Malaria in
that year (UNDP, 2005).
Table 2: Selected indicators of achievements in health and human
development, different regions of the world
Note: LDCs  = Least developed countries; OECD = Organisation for Economic
Cooperation and Development.
Source: UNDP (2005), Table 9; UNDP (2007), Tables, 5, 7 and 10.
LDCs 766 53 35 3.2 452
Developing
Countries 5215 66 17 1.3 289
Sub-Saharan
Africa 723 49 32 7.3 487
South Asia 1587 63 21 0.7 306
India 1134 63 20 0.4 – 1.3 287
China 1313 72 12 0.1 245
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Technological advances in pharmaceuticals and biotechnology
open up tremendous opportunities for solving the problems of ill health
and malnutrition in the developing world. However, while majority of the
world’s population in need of medicines live in developing countries,
pharmaceuticals industry is effectively controlled by a small number of
MNCs headquartered in the developed world. In 1999, the share of high
income countries (according to World Bank definition) in global
pharmaceutical production was 92.9 percent, middle and low income
countries accounting for only the remaining 7.1 percent. Research and
development in pharmaceuticals is carried out largely in developed
countries. Of the total global spending on health R&D, 42 percent is12 13
privately funded, 47 percent is funded by the public sector in high-income
and transition countries, and only 3 percent is financed by the public
sector in low- and middle-income countries (WHO, 2004, pp. 5-13).  Not
surprisingly, R&D activities are overwhelmingly directed toward the health
needs of the rich in industrialized countries, toward lifestyle-related and
convenience medicines. There are many ‘tropical diseases’ (also referred
to as ‘neglected diseases’) such as dengue, diphtheria and malaria, which
primarily affect people in poorer countries, but these diseases are given
very low priority in pharmaceutical R&D (Lanjouw and MacLeod, 2005).
It is pointed out that only 10 percent of the worldwide spending on
pharmaceutical R&D is directed toward 90 percent of the global disease
burden (WHO, 2004, pp.18-19).
Such unevenness in pharmaceuticals research and production
capabilities gets reflected in the statistics on consumption of medicines.
In 1999, low-income countries, accounting for 40.2 percent of world
population, had a share of just 2.9 percent in global consumption (in
value terms) of medicines. Imbalances between high- and low-income
countries in consumption of medicines have been worsening, as shown
through the data for the years 1985 and 1999 in Figure 1. It is reported
that over one-third of world’s population purchased less than one percent
of the pharmaceuticals sold worldwide. In 1999, 1725 million people in
the world, including 649 million in India, 267 million in Africa and 191
million in China, were without access to essential medicines (WHO, 2004,
pp.31-3 and 62).
Figure 1: Shares of high-income and low-income countries in
world population and global consumption (in value) of











































With the advent of biotechnology, healthcare and pharmaceutical
industries are undergoing fundamental changes. The core scientific
principles underlying pharmaceutical innovations are shifting ‘from fine
chemistry towards molecular biology’ (Cooke, 2005, p.333). Rather than14 15
waiting for ‘chance discoveries’, pharmaceutical innovation today is
increasingly characterized by ‘rational drug design’ in which dedicated
biotech firms play a prominent role (Cooke, 2005). However, dedicated
biotech firms operate under the shadow of big pharmaceutical
corporations. The therapeutic products they develop are licensed out to
the big corporations. Biotech firms are located in clusters, and most of
the leading clusters in biomedical sciences are in North America and
Western Europe.
Advances in biotechnology also raise hopes for dramatic
improvements in agricultural productivity, which are essential to meet
the food supply requirements of a growing world population. However,
research on agricultural applications of genetic engineering, including
Genetically Modified (GM) crops, is carried out almost entirely by
US-based MNCs. This is in contrast to the case of earlier innovations in
agriculture including those of non-GM hybrid crop varieties, which were
born out of publicly funded research. The extreme dominance of US
multinationals in GM research as well as concerns regarding biological
safety and biopiracy largely explains the unpopularity of GM crops in
Europe and in a majority of developing countries (Bernauer, 2003). GM
research has so far covered only a limited number of crops, importantly,
soybeans, maize and cotton, while it has almost neglected tropical
subsistence crops such as cassava, millet and cowpeas grown by poor
farmers in developing countries. Similarly, while GM research focuses
almost exclusively on pest resistance and herbicide tolerance, some of
the issues pertinent to developing country agriculture such as drought
resistance have not been on its agenda (Paarlberg, 2001). Thus, the
general picture in pharmaceuticals and biotechnology industries is one
of neglect of developing country needs. It is against this general context
that the case studies of pharmaceuticals and biotechnology industries in
India and China presented in the following sections assumes relevance.
4. Pharmaceuticals Industry in India
India’s  pharmaceuticals industry  has been growing at a
remarkably fast pace. India supplies 8 percent of the world’s output (in
volume) of drugs, and 22 percent of the world’s output of generic drugs
(Sampath, 2005, p.15; Grace, 2004). As per the latest available statistics
(for 2007), there were 75 manufacturing units in India approved by the
United States Food and Drug Administration (FDA); India has the largest
number of FDA approved manufacturing facilities in any country other
than the United  States. Recent reports indicate that the Indian
pharmaceutical industry consists of 300 large to moderate firms; the
number of firms rises to 24,000 if small firms are also included.4 In
2005-06, India exported drugs, pharmaceuticals and fine chemicals worth
US$4.9 billion to a large number of countries including the United States,
United Kingdom, Germany, Russia and China (CMIE, 2006).
4.1 State Intervention and Growth of Pharmaceuticals Industry
in India
State intervention has been  an essential feature in  the
development and growth of the  Indian pharmaceutical industry
4 See the report ‘Pharma Industry Aims High: Headed for a Place in the Global Top
10: Country Focus: India’, Chemical Week, November 21, 2007, p. 38. See also
Grace (2005), p.8.16 17
(Chaudhuri, 2005). A major component of this state intervention relates
to the introduction of the Indian Patents Act of 1970 (which came into
effect in 1972). Until 1970, the Patents and Design Act 1911 — a law
framed during the British colonial period which guaranteed product
patenting rights to drug companies – was a serious drag on the growth
of domestic pharmaceutical firms in India. Production and distribution of
medicines in India was almost fully under the control of MNCs, and prices
of medicines sold in India by the MNCs were reported to be one of the
highest in the world.5 The Indian Patents Act of 1970 brought in major
changes. Section 5 of the 1970 Act disallowed product patenting in the
case of drugs and food products; only the processes for manufacturing
these products were eligible for patents, according to the Act.  The period
for which patents were granted was reduced from sixteen years to five
years (from the date of patent granting or seven years from the date of
patent application). The 1970 Act made it mandatory for the patent holder
to start domestic manufacturing using the patented process within three
years from the date of sealing of the patent as well as to issue licenses
to local manufacturers (for a royalty) after the three-year period (Lanjouw,
1997, p.51; Chaudhuri, 2005, pp.36-8).
Pharmaceutical manufacturing and research organizations set
up by the Indian government from the 1950s created a supportive
environment for the growth of the domestic industry. Hyderabad’s
emergence as a centre for bulk drug manufacturing was aided by the
early establishment of public sector units such as Indian Institute of
Chemical Technology (IICT) and Indian Drugs and Pharmaceuticals Limited
(IDPL) (inaugurated in 1956 and 1961 respectively) in the city. India’s
Council of Scientific and Industrial Research (CSIR) developed many
technologies that were used by even the top pharmaceutical firms in
India. At the same time, through a number of regulations in the 1970s,
the government discouraged MNCs presence in low technology areas,
leaving these sectors for domestic firms (Chaudhuri, 2005). In addition,
the government’s Drug Price Control Order (DPCO) of 1970 took steps to
check the unwarranted escalation of pharmaceutical prices.6
Under the protective cover of state support, domestic firms
developed reverse engineering capabilities in chemicals-based processes
for pharmaceutical production. Many of them grew to become leading
producers of generic drugs and started supplying medicines for the Indian
market. In 1970, of the top ten pharmaceutical firms by retail sales in the
Indian market, only two were Indian firms while the rest eight were
subsidiaries of multinational companies (Lanjouw, 1997, p.3). The shares
of domestic firms and MNCs in India’s pharmaceuticals market by sales
were 32 per cent and 68 per cent respectively in 1970. By 2004, these
shares were altered upside down: the share of domestic firms rose to
77 percent while the share of MNCs correspondingly declined to 33 percent
(see Table 3).
More importantly, domestic pharmaceutical companies were able
to manufacture and sell generic versions of medicines at very low prices
5 According to Kefauver Committee of the United States, cited in Keayla (2005).
6 The DPCO, which underwent several modifications, was finally replaced by the
National Pharmaceuticals Policy of 2002.18 19
in India. Drug prices in India are much lower than the prices of similar
drugs in several countries including the United States and United Kingdom
as well as Pakistan and Indonesia (see Table 4). India has been a major
exporter of relatively cheap active pharmaceutical ingredients (APIs) and
pharmaceutical formulations of several medicines, notably vaccines and
anti-retrovirals (ARVs) (Grace, 2004, pp.13-5). The Indian pharmaceutical
firm CIPLA supplies ARVs to over 250,000 HIV patients in poor countries.7
When Ranbaxy, another leading Indian pharmaceutical firm, announced
plans to launch the cholesterol drug atorvastatin in the US and UK, the
media in the UK welcomed it as a move that would result in substantial
financial savings to that country’s National Health Service (Tomlinson,
2005).
7 See <www.cipla.com>, accessed 15 January 2006.
Table 3: Selected Indicators of Growth of Domestic Firms in
India’s Pharmaceuticals Industry, 1970-2004
1970 1998 2004
Share in % of domestic firms in India’s
pharmaceuticals market by sales 32 60 77
Number of domestic firms among top 20
firms by pharmaceutical sales in India 6* 12* 15
Notes: *Statistics refer to the years 1971 and 1996 respectively.
Sources: Chaudhuri (2005), p.18 and Lanjouw (1997), p.39. The
statistics cited in Chaudhuri (2005) are based on the following:
for 1970, Ministry of Petroleum and Chemicals (1971), p.1;
for 1998, Kalsekar (2003); for 2004, Sudip Chaudhuri’s
calculation using ORG-MARG (2004). The statistics relating to
top 20 firms by pharmaceutical sales was cited in Lanjouw
(1997) and was sourced from ORG, Mumbai.
Table 4: Prices of selected drugs in India and other countries, in
Indian Rupees, 2002-2003
Drugs and
dosage India Pakistan Indonesia UK US
Ciprofloxacin HCL, 29 423.9 393.0 1185.7 2352.4
500  mg (1.0) (14.6) (13.6) (40.9) (81.1)
Diclofenac  Sodium, 3.5 84.7 59.8 61.0 674.8
50 mg (1.0) (24.2) (17.1) (17.4) (192.8)
Ranitidine,  150  mg 6.02 74.1 178.4 247.2 863.6
(1.0) (12.3) (29.6) (41.1) (143.5)
Notes: Ciprofloxacin HCL is an Anti-infective. Diclofenac and Ranitidine
are  anti-ulcerants.
Figures in brackets show prices as indices with price in India = 1
Drug prices refer to the following years: for India, 2003; for
Pakistan 2002-03; for US, 2002;  and for UK February 2004.
Retail prices in India and wholesale prices in other countries were
considered.  All  prices  were  converted to  Indian  Rupees.
Source: Centre  for  Study  of Global  Trade System  and  Development
(2004)  and  Keayla  (2005).
4.2 The TRIPS Agreement and Changes in India’s Patent Laws
The WTO’s Agreement on Trade Related Aspects of Intellectual
Property Rights (TRIPS) came into effect on 1 January 1995. As WTO
members, India and other developing countries were obliged to bring in
legislations in line with the TRIPS provisions over a ten-year period.
‘Mail box’ facilities and exclusive marketing rights were to be introduced
from 1 January 1995 itself; provisions regarding rights of patentee, term
of patent protection, compulsory licensing and reversal of burden of proof
had to be legislated before 1 January 2000; and laws protecting product
patents had to be legislated before the end of the ten-year transition
period (therefore, before 1 January 2005).20 21
The Indian Parliament debated the TRIPS provisions intensely,
in the process delaying the introduction of obligatory legislations in several
instances. The Parliament passed the Patents (Amendments) Act 1999,
the Patents (Amendment) Act 2002, the Indian Patents Ordinance of 2004,
and the Indian Patents (Amendment) Act of 2005. India’s patent rules
were made less liberal over the years with the introduction of these
legislations. The Patents (Amendment) Act 2002 had made 64 changes
to the Patents Act of 1970. There were criticisms that some of the new
legislations had not even made full use of the flexibilities that the TRIPS
regime had allowed for developing countries; there were also widespread
concerns on the implications of these laws for public health. The Indian
Patents Ordinance of 2004 had allowed patents on combinations and
crystalline versions of known molecules; reduced the grounds on which
a patent could be opposed during the pre-grant period; and required
least developed countries (LDCs) to issue compulsory licenses for
importing generic drugs from India. All these provisions generated strong
criticisms as being unduly favourable to patent owners. The Indian Patents
(Amendment) Act of 2005, which introduced product patent rules, rectified
some of the drawbacks contained in the Ordinance of 2004 (Chaudhuri,
2005, pp.70-116; Grace, 2005).
The battle on patent rules is still going on in India. Multinational
pharma corporationss lobby for stricter patent laws and their stricter
implementation. On the other side are a number of activists and
international organizations raising concerns on public health. Currently,
there is strong pressure particularly from the MNCs to bring in new
provisions that allow data exclusivity in India. Data exclusivity specifies
that the test data submitted by the patentee to the regulatory agencies
will not be disclosed to the public. Generic drug firms, which need to
prove bioequivalence of their generic versions of drugs, will be affected
by this rule. Also data exclusivity allows the patent holders to extend
their monopoly rights even after the expiry of the patent term (Chaudhuri,
2005, pp.80-3; Keayla, 2005).8 At the same time, in August 2007, an
Indian Court dismissed an appeal from the pharmaceuticals giant Novartis
regarding patent cover for its drug Gilvec; the Court pointed out that
incremental innovations will not be eligible for patent protection. This
ruling has raised the hopes for health activists worldwide who argue that
a strict patent regime is a deterrent to the supply of affordable medicines
(Cookson and Yee, 2007).
4.3 TRIPS and Strategies of Indian Pharmaceutical Firms
With the introduction of TRIPS-compliant product patent rules in
2005, Indian pharmaceutical industry can no longer rely on its reverse
engineering skills alone for future growth. India’s domestic pharmaceutical
firms have been growing in technological capabilities, and this enabled
them to make two fundamental changes to their business models during
the years of TRIPS implementation (1995-2005).9 First,  leading
pharmaceutical firms in India have been making higher allocations for
R&D spending and trying to acquire patents abroad. In the case of
Dr. Reddy’s Laboratories, an Indian firm, R&D charges as a proportion of
8 See also Dhar and Gopakumar (2006).
9 See Lanjouw (1997), Sampath (2005), and Chaturvedi et al. (2007) (which provides
a detailed update on the strategies of Indian pharmaceutical firms before and after
TRIPS). See also Ramanna (2005) on the emergence of a strong pro-patent lobby
in the country prior to 2005.22 23
sales revenue were 0.6 percent and 2.8 per cent respectively in the three
year periods ending in 1987 and 1994-95. The proportion rose to 11.0
percent in the three year period ending in 2005-06.10 Ranbaxy made 698
patent filings in the first nine months of 2005 compared to 428 patent
filings in the first nine months of 2004.11 Secondly, rising R&D intensity
went hand in hand with export orientation, notably to the regulated
markets of North America and Europe. For instance, in 2005, United States
and Europe, together, accounted for 45.2 percent of Ranbaxy’s total global
sales (of US$1178 million).12  The preference shown  by  Indian
pharmaceutical firms to developed country markets is evident in Figure 2.
10 See Dr. Reddy’s Laboratories Ltd. Annual Reports, various years.
11 See <www.ranbaxy.com>, accessed 15 January 2006.
12 See Ranbaxy Annual Report 2005, downloaded from <http://www.ranbaxy.com>,
accessed on 17 January 2007.
Figure 2:  Exports of drugs, pharmaceuticals and fine chemicals
by India to selected developed and developing countries,
































Notes: Selected developed countries: United States, Germany, United
Kingdom and Canada.
Selected developing countries: Nigeria, Viet Nam, Sri Lanka,
Pakistan, Bangladesh and Nepal.
These 10 countries have figured in the list of 21 leading
destinations for India’s exports of drugs, pharmaceuticals and
fine chemicals throughout the period under study.
Source: Calculations based on CMIE (2005), p.69.
Indian pharmaceutical industry’s international ambitions have
received a  boost also  from the  changing nature  of the  global
pharmaceutical business. The discovery of a new drug is an extremely
lengthy and financially-risky process. Bringing an experimental drug into
the United States market takes an average of 12 years. According to
some reports, of the 5000 drug compounds that are evaluated at the24 25
preclinical stage, five compounds enter the phase of clinical trials, and
only one compound ultimately gets the approval for marketing from the
US Food and Drug Administration (FDA).13 Reports in 2006 indicate that
the cost of development and subsequent introduction into the market of
a new drug compound range between US$ 0.8 to 1.7 billion (McKinnell,
2006). To reduce the cost of new drug discovery, pharmaceutical MNCs
are entering into strategic alliances with smaller pharmaceutical firms,
biotech companies and academic centres. Novartis, for instance, claims
to have more than 400 collaborations in over 20 countries.14 India’s cost
advantages in pharmaceuticals R&D are encouraging global corporations
to form research partnerships with Indian firms. Outsourcing of clinical
trials to India has witnessed an especially fast growth; the number of
ongoing clinical trials in India has risen to 270 in 2007 (Yee, 2007).
The strategies pursued by India’s leading drug makers today
consist of collaboration as well as, in some cases, competition with
Western pharmaceutical MNCs. Even the leading Indian drug firms are
much smaller compared to pharmaceutical corporations, and they do not
possess the skills or the resources to carry out the entire process of new
drug discovery.15 Therefore, Indian pharmaceutical companies conduct
research and develop new molecules, but instead of proceeding further
into the long and financially risky clinical trial and regulatory stages, they
license out the molecule to bigger pharmaceutical MNCs (Chaudhury,
2005). At the same time, the high returns in the generic drugs market in
North America and Western Europe is highly attractive to Indian drug
firms. They have challenged big pharmaceutical corporations in the
market for generic drugs in the West. Also, to consolidate their generic
drugs business, many Indian drug firms have been pursuing an aggressive
strategy of overseas acquisitions over the past several months.16
Success, however, is not guaranteed for India’s leading drug
makers in the generic business. Originator drug companies, some of
which have launched their own branded generics, unleash long and
expensive legal battles against their generic competitors (Rai, 2003;
Jack, 2005). For originator drug companies, patent litigation to delay the
entry of generic competitors even by a few months is a high return-zero
risk strategy, whereas for generic drug firms, patent related legal battles
involve high returns as well as high risks (Chaudhuri, 2005, pp.205-6).
Many of the top Indian drug firms are fighting IPR-related legal battles,
incurring heavy costs. Ranbaxy has been engaged in a legal wrangle
over its generic version of atorvastatin calcium, an anti-cholesterol drug,
which Pfizer claims has violated its patent on Lipitor. Ranbaxy’s fortunes
have waxed and waned in this long-drawn-out litigation that is still being
fought in the courts of several countries. Reports suggest that Ranbaxy
spent US$30million on legal expenses in the year 2005, while the
company’s R&D expenditure, for the year 2004, was US$75.1 million.17 13 According to information given at the Website of Alliance Pharmaceutical
Corporation. See <www.allp.com/drug_dev.htm>, accessed 15 July 2006.
14 See <www.allp.com/drug_dev.htm>  and <www.nibr.novartis.com/OurScience/
drug_development.html> , accessed 16 September 2006.
15 For example, in 2005, sales revenue of the Indian company Ranbaxy was US$1.17
billion and that of Pfizer was US$51.3 billion. See Knowledge@Wharton (2006).
16 Information obtained from various issues of Indian Industry: A Monthly Review
for the year 2007, published by Centre for Monitoring Indian Economy, Mumbai.
17 See Mahapatra (2006) and Ranbaxy’s website <www.ranbaxy.com>, accessed 14
December 2005.26 27
Similarly, Dr. Reddy’s reportedly spent US$12m on legal bills in 2004,
which was equivalent to a quarter of the company’s R&D budget
(Economist, 2005).
4.5 The Future of the Industry and the Supply of Affordable
Medicines
It is doubtful whether the leading Indian pharmaceutical firms
will ever grow to match the levels of Western pharmaceutical MNCs,
given the hurdles posed by the IPR-regime and the disparities between
the two in financial and research capabilities. No Indian firm has, so far,
been able to fully develop an original drug, although some firms are
close to achieving this feat. More crucially, a large number of relatively
small Indian pharmaceutical firms are facing grim growth prospects in
the post-TRIPS phase, and this is raising important questions for the
future of the industry in India. It will be difficult for these small Indian
firms to repeat the successes of their bigger counterparts in the export
markets for generics: the regulatory barriers to entry and the stiff
competition in the generic drugs markets in developed countries are
important road blocks (Chaudhuri, 2005). In the domestic market, product
patent legislations will eventually rein in the growth of small Indian firms.
Manufacturing drugs for the domestic market using process innovations,
the strategy that helped leading Indian drugs makers during their
formative years, is not possible any longer.18 Furthermore, there is
growingly intense competition in India’s pharmaceutical markets, raising
the costs of entry to smaller firms.  In recent years, the  Indian
pharmaceuticals industry has witnessed a significant increase in mergers
and acquisitions (M&As) and a consequent rise in concentration ratios.19
Smaller Indian pharmaceutical firms are also affected by the tightening
of regulatory restrictions in the Indian market as well as in the export
markets of countries such as Brazil and Korea.20
A bigger concern arising from the recent developments in the
pharmaceuticals industry relates to their implications for the supply of
medicines to poor patients. The advocates of a strict patent regime have
argued that with the implementation of product patent rules, MNCs will
step up investment in research on neglected diseases. However, this does
not appear to have occurred in India. In a survey of 31 large pharmaceutical
companies operating in India (which included companies under Indian
ownership and MNC subsidiaries), Lanjouw and MacLeod (2005) found
that only 10 percent of the entire R&D investments by these companies in
2003-04 were targeted at developing country markets and tropical
diseases. At the same time, multinational pharmaceutical corporations
are sensing a major market opportunity for the supply of medicines for
global diseases such as cancer and cardiovascular diseases prevalent
among India’s large middle class population. It appears that MNCs’ interests
in India are limited to its growing pharmaceuticals market, and not so
much in the country’s potential as a pharmaceuticals manufacturer. MNC
investments in India in the manufacture of bulk drugs have not recorded
any appreciable increase in recent years (Chaudhury, 2005). Meanwhile,
worries are surfacing about the outsourcing of clinical trials to India.
18 Interview with Mr. B. K. Keayla, 11 December 2006.
19 Concentration ratios of the largest four and largest eight firms in Indian
pharmaceutical industry increased after 1995-96. See Chadha (2006).
20 Interview with Mr. Lalit Kumar Jain, an entrepreneur having long association with
small-scale pharmaceutical industry in India, New Delhi, 10 December, 2006.28 29
Terming it as ‘a new colonialism’, Nundy and Gulhati (2005) have discussed
some of the dangers of conducting clinical trials among poor and illiterate
patients without putting in place a proper regulatory system.
The problems emerging as part of a post-TRIPS scenario are
likely to become more severe in the future. Grace (2005), after examining
previous studies, concluded that the share of patented drugs in the market
value of medicines supplied in India in 2005 was in the range of 10 to 15
percent. However, over time, as new medicines are invented, a greater
proportion of the overall Indian market for medicines will come under
the patent cover. New medicines are necessary in the treatment of most
diseases including tuberculosis and malaria as older medicines turn
ineffective with the setting in of drug resistance. In the case of combination
drugs, even if only one drug in the combination is patent protected, that
will escalate the cost of the entire therapy (Grace, 2005, pp.16-20). The
pressures on the supply of affordable medicines brought about by changes
in patent rules are reflected in the words of Dr. Y. K. Hamied of CIPLA, an
Indian company that is an important supplier of medicines for tropical
diseases:
“…..[India’s product patent legislation implemented in 2005]
will deprive the poor of India and also third world countries
dependent on India, of the vital medicines they need to
survive.…It will lead to a systematic denial of drugs to the
three billion in the poorer nations, an act tantamount to
selective genocide by the year 2015".21
5. Pharmaceuticals and Biotechnology in China
Pharmaceuticals industry is expanding fast in China. According
to Nolan and Yeung (2001), China’s pharmaceuticals industry picked up
in growth after the mid-1980s. This was a period when the government
relaxed state controls over the industry and generated competition among
the suppliers. The structure of ownership was gradually liberalized as
well, and raising funds on the stock market and mergers and acquisitions
became instruments through which the pharma industry further
consolidated its position in China (Nolan and Yeong, 2001). There were
4296 pharmaceutical manufacturing facilities in China in 2003. Domestic
industry  supplies almost  70 percent  of the  Chinese market for
pharmaceutical products. Chinese firms have acquired great expertise in
the manufacture of bulk drugs and active pharmaceutical ingredients
(APIs). China is the world’s second largest producer of pharmaceutical
ingredients, and the largest producer of many pharmaceutical products
including penicillin (producing 60 percent of world output), vitamin C (50
percent of world output), terramycin (65 percent of world output),
doxycycline hydrochloride and cephalosporins (Grace, 2004, pp.13-4).
The countrty is promoting innovative research in the area of traditional
Chinese medicine; in April 2004, Chinese authorities approved the first
HIV/AIDS treatment derived from traditional Chinese medicine (Grace,
2005, p.10-1).
At the same time, however, the strength of China’s domestic
pharmaceuticals industry should not be overstated. Nolan (2002), while
making a note of the impressive growth of the Chinese pharmaceutical
firm Sanjiu during the 1990s, was quick to add that firms like Sanjiu
21 Address by Dr. Y. K. Hamied, Chairman and Managing Director, CIPLA,
Sixty-Ninth Annual  General  Meeting,  6  September  2005, at  <http://
www.cipla.com/corporateprofile/financial/cm69.htm>, accessed 14 December
2005.30 31
would face massive hurdles as they compete with multinational
pharmaceutical  giants. Nolan  (2002) points  out  that  China’s
pharmaceuticals industry is “relatively small and highly fragmented”, and
that the revenues and research capabilities of Chinese firms are only a
tiny fraction of multinational companies (Nolan, 2002: 123).
5.1. Pharmaceuticals Industry and the Evolution of IPR Regime
in China
Significant steps in the direction of establishing a patent regime
began in China only after the late 1970s.22 Chinese government’s gradual
implementation of an intellectual property rights (IPR) policy was shaped
by two factors: a commitment to the development of domestic capabilities
in science and technology, on the one hand, and, international pressure,
particularly from the United States, pushing China to a strict patent regime,
on the other. China joined the World Intellectual Property Organization
(WIPO) in March 1980 and the Paris Convention for the Protection of
Industrial Property in March 1985. The first Patents Law was introduced
in China in 1984. This law, which came into effect on 1 April, 1985, was
rather narrow in its scope. It did not offer product patent protection to
inventions in pharmaceuticals, chemicals, food, beverages and condiments
(in much the same manner as India’s Patents Act of 1970). The stipulations
contained in the 1984 law ensured that foreign investments into China
came along with technology transfer and contributed to the building of
domestic innovative capabilities (Kong, 2005).
China introduced a stricter patent regime in 1992. In the early
1990s, China was integrating itself more closely with the world economy,
and a commitment to IPR protection was important to attract foreign
investments. Also, from being an importer of technologies, China was
gradually emerging as an exporter of technology-intensive products (Kong,
2005). Grace (2005) noted that the implementation of IPR policies in China
was influenced, to a great extent, by the country’s bilateral negotiations
with the United States on trade and investment. Product patenting rules
came into effect in China in 1993 – more than ten years before TRIPS
would have required the country to implement them. An agreement
between China and the United States in 1999 on China’s WTO accession
contained proposals for early introduction of TRIPS-compliant IPR rules.
China joined the WTO in 2001, and the country introduced patent laws
incorporating TRIPS provisions by the end of 2002. China was not given
the transition period that was granted to other developing countries (Grace,
2005, pp. 21-5; Kong, 2005). Chinese laws extend patent protection for
twenty years and data exclusivity for six years (Grace, 2004).
Despite the implementation of product patent laws, China has
been able to manufacture pharmaceutical ingredients that contribute to
the supply of essential medicines for the developing world. China is an
important producer of a wide variety of raw materials for second-line
antiretrovirals (ARVs) (second-line ARVs are necessary for treatment
once the patient develops resistance to first-line treatment).23 One of the
22 See <http://www.china.org.cn/e-white/20050421/index.htm>, accessed 15 January
2006.
23 See ‘India, China or Brazil — Who will Produce the Second Line ARVs?’, Health
and Development Networks, July 12, 2005, at <http://www.aidsmap.com/en/news/
24B33FA6-89CB-42BA-880F-18D774FF85D6.asp>, accessed 17 September
2005.32 33
means through which China has bypassed the limitations set by patent
laws is by manufacturing intermediates only till the pre-API (active
pharmaceutical ingredients) stage. Patent protection is usually applicable
to APIs and finished products, and manufacturing a chemical that is one
step away from formulation into an API will not be a patent violation.
China then exports these intermediate pharmaceutical chemicals to other
countries where it is processed into APIs and finished products (Grace,
2005, pp.23-5).
However, pharmaceuticals industry in China is now facing
challenges from the patent regime. The United States continuously
pressurize China to improve its record on IPR enforcement. In December
2006, on the occasion of the fifth anniversary of China’s entry into the
WTO, the US Trade Representative, Susan Schwab, slammed China’s
record in enforcement of IPR rules. In a 100-page report submitted to
the US Congress, the US Trade Representative claimed that piracy of
software, videos, pharmaceuticals and other goods were rampant in China
and that the Chinese government did very little to curb such practices
(Weisman, 2006).  Reports suggest that in 2004, 2550 patent litigations
were filed in Chinese courts and that the rulings in 80 per cent of these
cases went in favour of the foreign patent holders (Seewald, 2006).
At the  same time, Western multinational pharmaceutical
companies are waking up to the tremendous market opportunities offered
by China’s large middle class population. Some estimates say that the
Chinese pharmaceuticals market would be the fifth largest in the world
by 2010.24 It is noted that over 20 of the world’s top 25 pharmaceutical
MNCs have already made their entry into China.25 Pharmaceutical
corporations are flocking especially to China’s eastern region comprising
the Yangtze River Delta, which enjoys high levels of purchasing power.26
With the introduction of product patent legislations, many multinational
pharmaceutical companies are outsourcing pharmaceutical research and
clinical trials to China. In 2007, there were a total of 510 clinical trials –
including completed and ongoing — outsourced to China (Jack and Yee,
2007). Companies like Novo Nordisk and Novartis have set up R&D facilities
in China to conduct research on global diseases by making use of China’s
cost advantage. They are equally keen on making inroads into the Chinese
market for pharmaceuticals.27
5.2 Health and Agricultural Biotechnology in China
China  has  embarked  on  an  ambitious programme  in
biotechnology. Life sciences has emerged as an important focus area in
China after the late 1970s, along with the state-wide promotion of science
and technology in the country during this period. The National Centre for
Biotechnology Development was established in 1983 under the State
Science and Technology Commission (this Centre later became part of
the Ministry of Science and Technology) (Gross, 1995; Chervenak, 2005).
By 1992, the government established seventeen national biotechnology
24 See ‘The Chinese Pharmaceuticals Market is Forecast to Become the World’s Fifth
Largest by 2010’, Biotech Business Week, July 9, 2007
25 Information from Biotech Business Week, May 14, 2007
26 See ‘Pall Magnifies Focus on Asia; Brings Top Talent, More Resources to the
Region to Address Growing Biopharmaceutical Market’, Business Wire Inc, March
21, 2006.
27 See the report ‘A Novel Prescription’ in the Economist, November 11, 2006; also
see Kjersem and Gammeltoft (2006).34 35
laboratories that were open to both domestic and foreign scientists; and
by 1995, there were approximately 1,000 biotechnology projects in China
employing over 10,000 scientists. According to a report in 1995, almost
one-third of the funds for biotechnology research in China came from
the Central Government (Gross, 1995). Between 1996 and 2000, the
Central Government invested over 1.5 billion Yuan (US$180 million) in
biotechnology (Economist, 2002). Local governments as well as quasi-
venture capital funds set up by the Central or local governments were
active in the promotion of biotechnology in China. The government also
encouraged Chinese firms to establish links with Western biotechnology
companies (Chervenak, 2005).
The government enhanced funding for the biotechnology sector
in China after 2000. As per estimates made in 2005, the Chinese
government spends more than US$600 million per year on biotechnology
R&D through its various funding programmes (Chervenak, 2005). This,
however, must be compared to the investment in biotechnology R&D in
the United States, which was US$15.7 billion in 2001 (Economist, 2002).
In 2002, according to estimates by China’s Ministry of Science and
Technology, 20,000 researchers were working in the field of life sciences
in the country; in the same year, biotechnology industry was reported to
be employing 191,000 people in the United States. Approximately another
20,000 Chinese biotechnology researchers were working abroad in the
year 2002, and their eventual return to the country was expected to give
a further boost to the biotechnology industry in China (Economist, 2002).
The major centres of China’s biotechnology industry include
Shenzhen, Shanghai and Beijing. Beijing Genomics Institute (BGI), which
was established as a state-sponsored research centre in 1999, took part
in the Human Genome Project; China was the only developing country to
participate in this project. Fudan University’s Human Genome Laboratory
in Shanghai is involved in the mapping and sequencing the human X
chromosome (Gross, 1995; Chervenak, 2005).
China is making rapid advances in the field of agricultural
biotechnology as well. Agricultural biotechnology began to receive
considerable policy attention in China from the late 1980s, as part of a
response to the enormous challenges of feeding a large population and
improving productivity in China’s small farms. Reports suggest that the
government under the former Prime Minister Zhu Rongji was highly
concerned about the growing dominance of US biotechnology firms in
Chinese agriculture.28 That the seeds improved over decades by Chinese
farmers could be appropriated by a few large US biotech corporations
was a worrying prospect to policy makers in China (Chen, 1999).29 Under
these circumstances, the government stepped up funding for research
on GM crops that are highly suited to local growing conditions. In 1999,
government expenditure on agricultural biotechnology research in China
was US$112 million. This figure was nearly ten times the agricultural
biotechnology research budgets of India and Brazil in the same year,
28 In the late 1990s, the US biotechnology companies were in a dominant position in
Shijiazhuang, Hebei and Langfang area. Chinese biotechnology firms had the upper
hand in Henan and Anhui Provinces. See Chen (1999).
29 These are the views expressed by Chen Zhangliang, Vice Chancellor and Professor
of Beijing University, in an interview he gave in 1999. See Chen (1999). According
to Chen Zhangliang, the Chinese Premier expressed his concerns regarding US
multinational corporations’ dominance in Chinese agriculture after a visit to the
north-eastern province of Jilin.36 37
although it was still considerably smaller than the US$1-2 billion that the
United States spent  in 1999 on plant biotechnology research (Karplus,
2003).
Public investment in biotechnology research in China has
produced impressive results. As per reports in 2002, Chinese research
institutes developed 141 types of GM crops, of which 65 were undergoing
field trials. Today, China is carrying out research on genetically modified
tomatoes that take longer to rot (which helps in their transportation,
processing and storage); and vitamin A enriched rice that will help
improve nutrition in many parts of the developing world. China has
recorded great success in research on Bt cotton. Chinese research
laboratories introduced 18 varieties of pest resistant Bt cotton by 2002
(Karplus, 2003). Area under Bt cotton cultivation in China increased from
1.5 million hectares in 2001 to 3.3 million hectares in 2005, and over 4
million small-scale farmers were involved in Bt cotton cultivation in China
in the year 2001 (Karplus, 2003).
5.3 India and China: Interactions in Pharmaceuticals and
Biotechnology
Over the past few years, there has been a growing engagement
between India and China in the economic sphere, and this has extended
to the pharmaceuticals and biotechnology sectors as well. While several
major Indian pharmaceutical firms have set up joint ventures and
production facilities in China, China has emerged as a very important
supplier of APIs and bulk drugs for pharmaceuticals industry in India. As
a source of India’s imports of medicinal and pharmaceutical products,
China’s share is the highest, at 34.6 percent in 2005-06, having risen
from 6.2 percent in 1993-94. Correspondingly, as a destination for India’s
exports of drugs, pharmaceuticals and fine chemicals, China’s share
increased from 0.4 percent in 1993-94 to 3.5 percent in 2005-06 (CMIE,
1997; CMIE, 2005; CMIE, 2006).
It may be noted that the import of bulk drugs and APIs from
China is viewed as a threat by many small-scale bulk drug manufacturers
in India. Small-scale drug firms in India have been encountering several
growth constraints (some of which have been discussed earlier), which
are aggravated by competition from Chinese bulk drug makers. Chinese
firms are large-scale producers of many of the intermediates for bulk
drug manufacturing, enjoying clear advantages in their specific areas of
production. At the same time, industry observers say that India possesses
superior technology and skills in pharmaceutical formulations.
Representatives of small-scale pharmaceutical industry in India have
expressed fears about Indian drug companies transferring technological
skills to their Chinese counterparts.1
While some of the genuine growth concerns of small-scale drug
makers in India need to be addressed, these should not be a reason to
stall greater positive interaction between pharmaceuticals industries in
India and China. Rather than competing with each other, pharmaceutical
firms in the two countries must seek avenues for cooperation at the
higher plane of innovation. China’s biotechnology sector and India’s
1 Interview with Mr. Lalit Kumar Jain, New Delhi, December 10, 2006. See also
Chaudhuri (2005).38 39
pharmaceuticals industry should feed into each other’s expertise. Together,
they can strive for pharmaceutical innovations that address the health
needs of poor patients in the developing world.
India and China can enhance their levels of engagement in
agricultural biotechnology as well. India has given approval for commercial
sale of 12 varieties of Bt cotton hybrids, all of which carry the gene
developed by the multinational giant Monsanto and marketed in India by
joint ventures (Mahyco-Monsanto) or sub-licensees of Monsanto
(Chaturvedi, 2005). However, reports from Andhra Pradesh indicate that
genetically modified (GM) cotton crops sold by Mahyco-Monsanto were a
failure in all the three years after the crop’s introduction. Many farmers
who took loans to buy GM seeds fell into huge debt-traps, but Mahyco-
Monsanto refused to compensate  the farmers  for their  losses
(Venkateshwarlu, 2006). Given such experiences, public and private sector
seed companies in India should strive to develop new GM technologies
that are suitable  for India’s  agro-climactic and socio-economic
environment. Collaboration with China, which has a very successful
programme in agricultural biotechnology, will be highly useful in this
regard. It is indeed a positive sign that, in March 2006, Agriculture
Ministers of India and China identified a number of areas for cooperation,
including agriculture biotechnology and exchange of plant and animal
germplasm.30
6. Conclusions
Globalization picks its winners and losers. According to Hoogvelt
(2001), populations and countries in the periphery of the global economy
progressively lose out while those who are part of the core strengthen
their positions. This chapter shows that the geography and nature of
innovation in the world economy are being fundamentally altered, in part
due to global rules on intellectual property rights enshrined in the TRIPS
and imposed on developing countries. India and China are emerging as
important destinations for global R&D on account of their large supplies
of highly skilled professionals and well-established science and technology
infrastructures. However, even as globalization of R&D gathers steam,
the poor in India, China and other developing countries are likely to be
left out of the new innovations, and big corporations in the West are
likely to consolidate their strengths.
The case studies of pharmaceuticals industries in India and China
presented in this chapter gives some credence to such apprehensions.
India has been a major supplier of generic drugs at affordable prices
within the country and outside, while China has been an important
producer of raw materials and active pharmaceutical ingredients for the
manufacture of several essential drugs, including anti-retrovirals for the
treatment of HIV/AIDS. Product patent rules in compliance with the TRIPS
were fully implemented in China by 2002 and in India by 2005 as part of
the WTO obligations of these countries. The leading Indian pharmaceutical
firms have responded well to the challenge of a strict IPR regime by
increasing their R&D spending and, simultaneously, targeting their sales
to the generic drugs markets in North America and Europe. However,
30 See the report ‘India, China Sign Agriculture Cooperation Pact’, Financial Times,
March 30, 2006.40 41
even as India’s top drug firms have been growing in technological
capabilities, they have also been shifting their focus away from the market
for medicines for poor patients. Smaller pharmaceutical firms in India
are facing several growth challenges, especially from the new IPR regime,
which hinder their potential to supply drugs for the domestic market.
The United States continuously pressurize China to improve its record on
enforcement of IPR rules. MNCs have increased their presence in India
and China, conducting contract research and clinical trials on global
diseases, eyeing the market of rich patients in these countries and outside.
Contrary to expectations, the implementation of TRIPS has not led to any
marked increase in MNCs’ R&D spending on neglected diseases. In fact,
there are growing uncertainties today on the future supply of affordable
medicines in the developing world.
In the light of such experiences, developing countries, importantly
India and China, need to initiate strong policy measures to counter the
negative effects of globalization of R&D. First, developing countries should
strengthen their national programmes in science and technology to ensure
that they are not overshadowed by global corporations. In this regard,
China’s attempt to reinvigorate the biotechnology sector is commendable.
Secondly, developing countries need to cooperate in the area of innovation.
Innovative  firms in  India and  China should  explore areas  for
complementary growth, rather than competing with each other to obtain
a slice of the market for R&D outsourcing. Blending India’s expertise in
pharmaceutical formulations and China’s growing capabilities in
biotechnology could result in new drugs for neglected diseases. China
and India have the responsibility for and, indeed, the capabilities to lead
developing countries in innovations that could solve world’s problems of
ill health and deprivation.42 43
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